Salute e Benessere
IBA reports solid Full Year 2024 results
- IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, today announces its consolidated results for the 2024 financial year.
* Including intercompany
Olivier Legrain, Chief Executive Officer of IBA, commented: “ We are pleased to report improved topline growth and a return to profitability in 2024. IBA successfully delivered its objective of accelerating backlog conversion across all business units, particularly in the Other Accelerators business.
IBA is at an inflection point and enters 2025 in a position of significant strength with a healthy balance sheet, all time high backlog and highly active pipeline. The building blocks for long-term profitability and sustainable value creation for all our stakeholders are now in place and enable IBA to share a 1-year guidance and an updated mid-term outlook.”
IBA's management team will host a hybrid event in English (conference call and webcast) to present the full year results, followed by a Q&A session.
The conference call will be held on Thursday, 20 March 2025 at 2:30pm CET / 1:30pm GMT / 9:30am ET / 6:30am PT as a Teams webinar and can be accessed online on this link.
If you would like to join by phone only, please dial (Phone conference ID 393 230 94#)
Belgium: +32 2 890 97 20
UK: +44 20 3321 5200
NL: +31 20 708 6901
LU: +352 27 87 00 02
US: +1 347-991-7591
FR: +33 1 70 99 53 51
The presentation will be available on IBA's investor relations website and on https://www.iba-worldwide.com/iba-full-year-2024-results-conference-call shortly before the call.
To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled webcast.
Financial calendar
Business Update Q1 2025 22 May 2025
Half Year Results 2025 28 August 2025
Business Update Q3 2025 20 November 2025
About IBA
IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the fields of proton therapy, considered as the most advanced form of radiation therapy available today, as well as industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,100 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.
IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com
For further information, please contact:
IBA
For media and investor enquiries:
ICR Healthcare
Amber Fennell, Angela Gray, Lucy Featherstone
+44 (0) 20 3709 5700
IBA@icrhealthcare.com
Following a review into revenue recognition treatment of third-party equipment under IFRS15, revenue is now recognized at the full sales price of third-party equipment. As a result of this change, there is an increase in both reported revenue and cost of goods, with a decrease in gross margin (with overall gross profit remaining the same). FY24 numbers reflect this new method of reporting and FY23 numbers have been restated. More information can be found in the Appendix.
Attachment
2321 Rosecrans Avenue. Suite 2200
90245 El Segundo Stati Uniti